Brain Mechanisms Underlying the Effect of the Motilin Receptor Agonist Erythromycin on Hunger in Normal Weight Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02212821|
Recruitment Status : Completed
First Posted : August 8, 2014
Last Update Posted : November 30, 2016
|Condition or disease||Intervention/treatment||Phase|
|Healthy Volunteers||Drug: Erythromycin Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Crossover Assignment|
|Primary Purpose:||Basic Science|
|Study Start Date :||September 2014|
|Actual Primary Completion Date :||September 2016|
Placebo Comparator: Placebo
- Functional brain images [ Time Frame: 40 min after intervention ]The functional brain images will be taken via functional magnetic resonance imaging (fMRI), and be analysed via a software called SPM.
- hunger scores [ Time Frame: every 10 minutes since the scan starts ]The hunger scores will be taken every 10 minutes since the scan starts via a 10 cm visual analogue scale.
- gut hormones [ Time Frame: every 10 min since the scan starts ]Peripheral blood samples will be taken every 10 min since the scan starts until the endpoint of the study to measure gut hormones (motilin, ghrelin, CCK, PYY, GLP-1) by radioimmuno-assay.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02212821
|Principal Investigator:||Jan Tack||University of Leuven|